Opinion|Videos|March 6, 2025
The PEACE-3 Trial
Panelists discuss how the PEACE-3 trial demonstrated meaningful clinical benefits with the combination of radium-223 and enzalutamide compared with enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC), showing both improved radiologic progression-free survival and a significant overall survival advantage of 7.3 months.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- The PEACE-3 trial investigated whether the combination of radium-223 and enzalutamide (RAD-ENZ) improves cancer progression over enzalutamide alone in patients with mCRPC.
- Please discuss the significance of a 31% reduction in radiologic disease progression or death with the combination of RAD-ENZ.
- Discussing the secondary end point in a bit more detail, the overall survival, from 35 to 42.3 months, was statistically significant. What does this mean in clinical practice?
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Alan Bryce, MD, highlights key phase 3 advances in prostate cancer
2
FDA clears Revi Extend implant for urgency urinary incontinence
3
FDA updates in urology: July 2026
4
FDA grants tentative approval to new cabozantinib capsule formulation
5